Frontiers in Immunology
2026
Qing Feng, Zhen Yuan, Qi An et al.
1 citation
Depression is increasingly recognized as a multifactorial disorder in which immune dysregulation contributes substantially to disease initiation, progression, and treatment response. Among the immune mediators implicated, serum inflammatory cytokines-including IL-1β, IL-6, TNF-α, IFN-γ, and C-reactive protein-have emerged as key links between peripheral inflammation and central nervous system...
Frontiers in Immunology
2025
David Qixiang Chen, José Adalberto Inzunza Domínguez, Juan Manuel Valle Uzeta et al.
3 citations
Multiple sclerosis (MS) is a debilitating neurodegenerative disease characterized by demyelination and neuronal loss. Traditional therapies often fail to halt disease progression or reverse neurological deficits. Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients...
Frontiers in Immunology
January 14, 2022
Faez Iqbal Khan, Fakhrul Hassan, Dakun Lai
34 citations
Various metabolites identified with therapeutic mushrooms have been found from different sources and are known to have antibacterial, antiviral, and anticancer properties. Over thousands soil growth-based mushroom metabolites have been discovered, and utilized worldwide to combat malignancy. In this study, psilocybin-mushroom that contains the psychedelic compounds such as psilacetin, psilocin,...
Frontiers in Immunology
July 14, 2015
Attila Szabo
153 citations
Classical psychedelics are psychoactive substances, which, besides their psychopharmacological activity, have also been shown to exert significant modulatory effects on immune responses by altering signaling pathways involved in inflammation, cellular proliferation, and cell survival via activating NF-κB and mitogen-activated protein kinases. Recently, several neurotransmitter receptors...